Key Performance Indicators Strategic priorities Key Performance Indicators Achieve Scientific Leadership Focus on innovative science in three main Transform our innovation and culture model NME Phase II starts progressions Phase III investment decisions therapy areas Focus on novel science, such as immuneFocus on Oncology: Cardiovascular, Renal mediated therapy combinations and precision and Metabolism: and Respiratory.
9 19 also selectively active in autoimmunity, infection and neuroscience.
Co-location near bioscience clusters at three 2018 9 2018 19 strategic centres in Cambridge, UK: Work across small molecules, Gaithersburg, MD, US: and Gothenburg, 2017 14 2017 9 oligonucleotides and other emerging Sweden helps to leverage our capabilities and 2016 16 2016 7 drug platforms, as well as biologic foster collaboration with leading scientists 1 medicines, including immunotherapies, and research organisations.
and innovative delivery devices that can See from page 127. offer choice to patients.
Accelerate through business development Work to reinforce our therapy areas and Prioritise and accelerate our pipeline strengthen our portfolio and pipeline through Accelerate and invest in key R&D targeted business development, including programmes.
At the end of 2018, eight NMEs collaborations, in-licensing and acquisitions.
were in Phase III pivotal Phase II or under NME or LCM project regulatory NME and major LCM regional approvals regulatory review, covering 15 indications.
Collaborate strategically to broaden and submissions in major markets accelerate the development of pipeline assets Three NMEs were approved in 2018.
Having externalisation and divest non-core assets met the targets for 2016 we had set ourselves to realise value.
28 23 in 2013, we are now on target to meet our longer-term goal of sustainably delivering 2018 28 2018 23 two NMEs annually by 2020.
2017 18 2017 19 2016 14 2016 11 Strengthen our early-stage pipeline through novel science and technology.
Note: The Clinical-stage strategic transactions We delivered three new molecular entities KPI, covering acquisition, licensing and NMEs in 2018 and are on target to meet divestment deals, has been removed from Achieve Scientific Leadership.
The impact of this ourgoal of sustainably delivering two activity is captured in the Group financial targets which better reflects the results, rather than a NMEsannually by 2020. separate measure for the number of deals.
A chieve Scientific Leadership from page 25: Therapy Area Review from page 50: Development Pipeline from page 212.
20 AstraZeneca Annual Report & Form 20-F Information 2018 Strategic Report Strategic Report Strategic priorities Key Performance Indicators Return to Growth Focus on Growth Platforms Oncology Aim to deliver six new cancer Emerging Markets Respiratory Emerging Markets Focus on delivering medicines to patients by 2020.
Since 2014, we innovative medicines by investing in have delivered five Oncology medicines to $6,891m $4,911m Emerging Markets capabilities, with a date: Lynparza, Tagrisso, Imfinzi, Calquence Product Sales Product Sales focus on China and other leading markets, and Lumoxiti that make a meaningful such as Brazil and Russia.
The ongoing difference to patients.
2018 $6,891m 2018 $4,911m transformation of our capabilities is supporting new medicines and improving Transform through specialty care, devices 2017 $6,149m 2017 $4,706m access and affordability.
and biologics 2016 $5,794m 2016 $4,753m Biologic medicines now account for about Respiratory Work to maximise pipeline half of our NMEs in development, potentially Actual growth CER growth Actual growth CER growth value, devices and medicines to fulfil unmet enhancing asset longevity.
A greater focus on 2018 12% 2018 13% 2018 4% 2018 3% medical need and improve patient outcomes innovative and differentiated delivery devices 2017 6% 2017 8% 2017 -1% 2017 -1% in asthma and COPD.
Includes all affords patients choice while ensuring 2016 0% 2016 6% 2016 -5% 2016 -3% respiratory brands.
Our new specialty care portfolio is expected to balance our strength New CVRM Since 2017, New CVRM in primary care medicines.
Growth Platform includes Brilinta, Onglyza New CVRM Japan franchise Onglyza and Kombiglyze, Farxiga franchise Farxiga and Xigduo, Exenatide Total Byetta and Bydureon, Symlin, Qtern, $4,004m $2,004m roxadustat, Epanova and Lokelma.
Product Sales Product Sales Japan Strengthen our Oncology franchise 2018 $4,004m 2018 $2,004m and work to maximise the success of our 2017 $3,567m 2017 $2,208m Diabetes medicines.
Reconciliation to thenumber used for calculating annual bonus is shown from page 127.
$18,464m 2 In 2018, Oncology Growth Platform Revenue from Growth Platforms of included the entire Oncology portfolio.
1 Prior years have been revised on $18,464 million in 2018 represented thisbasis.
84% of Total Revenue R eturn to Growth from page 29: TherapyArea Review from page 50.
AstraZeneca A As ntn ru aZ al R ene ec pa A ort & F nnuo arl R m 2 ep 0oF I rt & F nfoo rm rm 2 atio 0n 2 -F I0 n 1f7 S orma trta io te n 2 gy a 01n 8 K d Ke ey P y Pe er rf fo or rm ma an nc ce I e In nd di ic ca at to or rs s 21 Key Performance Indicators continued Strategic priorities Key Performance Indicators Be a Great Place to Work Evolve our culture Organisational structure % of Employees who would recommend Employee belief in our strategy Improve our employees engagement with employees within six management AstraZeneca as a great place to work ourPurpose and Values and promote greater steps of the CEO understanding of, and belief in, our strategy.
Simplify our business 89% 72% 83% Develop simpler, more efficient processes andflatten our organisational structure 2018 89% 2018 72% 2018 83% toimprove productivity, encourage 2017 88% 2017 70% 2017 81% accountability and improve decision makingand communication.
2016 80% 2016 82% 2016 74% 1 1 Attract and retain the best talent Source: December 2018 Pulse survey Source: December 2018 Pulse survey An inclusive environment that enhances across a sample of the organisation.
across a sample of the organisation.
2 2 Source: December 2017 Pulse survey ourability to attract and retain diverse Source: December 2017 Pulse survey across a sample of the organisation.
3 3 Source: December 2016 Pulse survey Source: December 2016 Pulse survey B e a Great Place to Work from page 38. across a sample of the organisation.
Do business sustainably Making science accessible Ethics: Non-compliance with our Health: Reaching people through our Environmental protection: Operational Deliver our business strategy in a way Code of Ethics Access to Healthcare programmes greenhouse gas GHG footprint that brings wider benefits to society and the planet.
56.6 12.0m 1,769 kt COe Focus on: per 1,000 employees in people Commercial Regions increasing access to healthcare for more people 2018 56.6 2018 12.0m 2018 1,769 kt COe furthering ethics and transparency 2017 41.4 2017 7.2m 2017 1,705 kt COe in everything we do 2016 50.7 2016 4.2m 2016 1,684 kt COe reducing environmental impacts on human health and the natural world.
1 Operational GHG footprint is emissions from all Scope 1, 2 and selected Scope 3 Connect our work with the sources.
UN Sustainable Development Goals and integrate our commitments into There were 2,042 instances, most of them Our Access to Healthcare programmes, Our 2018 operational GHG footprint met day-to-day business activities.
minor, of non-compliance with our Code including Healthy Heart Africa, Healthy ourtarget of progressing our Science Based ofEthics or supporting requirements in Lung, and Phakamisa, have reached Targets and represents a 0.4% reduction S ustainability from page 42. ourCommercial Regions by employees 12.0million people through education, fromour 2015 baseline.
screenings, diagnosis and treatment cumulatively since the start of each programme.
W e will review the Be a Great Place to We changed the title of our Environmental Our achievements are only made WorkKPIs in 2019 to evaluate appropriate protection KPI.
In line with World possible by a skilled and talented representation of the strategy.
Where Resources Institute GHG Protocol, a possible, we will continue to make updates carbon dioxide equivalent CO e number 2 team who live our Values and are on current indicators publicly available.
can be used to report on GHGs, and it is commonly called carbon.
At AstraZeneca, true to our Purpose.
A s disclosed in the 2017 Annual Report, the majority of our operational GHG wereassessed our Do business sustainably footprint is from non-CO GHGs so we 2 KPIs in 2018: arenow using the better representation ofGHG.
There is no change in the We added an Ethics & Transparency contentof our CO e reporting.
2 KPIto measure progress for our The retired KPIs are reported for continuity thirdsustainability focus area.
in the 2018 Sustainability Report on We expanded the Access to www.
HealthcareKPI to incorporate The retired KPIs are the Dow Jones moreofourprogrammes.
Sustainability Index rating and number ofpeople reached through only our HealthyHeart Africa programme.
22 AstraZeneca Annual Report & Form 20-F Information 2018 Strategic Report Strategic Report Strategic priorities Key Performance Indicators Achieve Group Financial Targets 1, Cost discipline Product Sales Net cash flow from operating activities Our aim is to deliver great medicines for patients while maintaining cost discipline $21,049m $2,618m and a flexible cost base.
2018 $21,049m 2018 $2,618m Maintain a progressive dividend 2017 $20,152m 2017 $3,578m Policy is to maintain or grow dividend per share.
2016 $21,319m 2016 $4,145m Actual growth CER growth Actual growth Maintain a strong balance sheet 2018 4% 2018 4% 2018 -27% Target a strong, investment-grade credit 2017 -5% 2017 -5% 2017 -14% rating and optimal cash generation.
external guidance and focus on commercial execution to drive Product Sales growth.
Product Sales and Externalisation Revenue make up Total Revenue.
2 Reconciliation to the number used for calculating annual bonus is shown from page 127.
3 First and second interim dividend for the year.
AstraZeneca Annual Report & Form 20-F Information 2018 Key Performance Indicators 23
